T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS Despite recent translation of immunotherapies into clinical practice, the immunobiology of hepatocellular carcinoma, in particular the role and clinical relevance of exhausted and liver-resident T cells remain unclear. We therefore dissected the landscape of exhausted and resident T cell responses in the peripheral blood and tumor microenvironment of HCC patients. METHODS Lymphocytes were isolated from blood, tumor and tumor-surrounding liver tissue from HCC patients (n=40, n=10 treated with anti-PD-1 therapy). Phenotype, function and response to anti-PD-1 were analyzed by mass and flow cytometry ex vivo and in vitro, tissue residence was further assessed by immunohistochemistry and imaging mass cytometry. Gene signatures were assessed in silico. RESULTS We identified significant enrichment of heterogeneous populations of exhausted CD8+ T cells (TEX) in the tumor microenvironment. Strong enrichment of severely exhausted CD8 T cells expressing multiple immune checkpoints in addition to PD-1 was linked to poor progression-free and overall survival. In contrast, PD-1 was also expressed on a subset of more functional and metabolically active CD103+ tissue-resident memory T cells (TRM) that expressed few additional immune checkpoints and were associated with better survival. TEX enrichment was independent from BCLC stage, AFP levels or age as a variable for progression-free survival in our cohort. These findings were in line with in silico gene signature analysis of TCGA-HCC tumor transcriptomes. A higher baseline TEX/TRM ratio was associated with disease control in anti-PD-1 treated patients. CONCLUSION Our data inform about a role of peripheral and intratumoral TEX - TRM dynamics in determining the outcomes of HCC patients. The dynamics between exhausted and liver-resident T cells have implications for immune-based diagnostics, rational patient selection and monitoring during HCC immunotherapies. LAY SUMMARY The role of the immune response in hepatocellular carcinoma (HCC) remains unclear. T cells, particularly effector or tissue-resident T cells can mediate protection against tumor cells, but are frequently dysfunctional and exhausted in cancer. To understand if these immune populations play significant roles in HCC, we investigated blood and tumor-derived T cells from HCC patients for different T cell types using advanced immune profiling technology able to characterize these populations in detail. We found that patients with a dominance of exhausted CD8+ T cells (TEX) had poor survival, in contrast to patients with a dominance of tissue-resident memory cells (TRM) and longer survival. This correlated with the molecular profile, metabolic and functional status of these cell populations. The enrichment of TEX was independently associated with prognosis in addition to disease stage, age and tumor markers. A high TRM proportion was also associated with better outcome to checkpoint therapy. Thus, these T cell populations are novel biomarkers relevant for HCC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Self-citationFinn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Self-citationYau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106
Kumar, B. V., Ma, W., Miron, M., Granot, T., Guyer, R. S., Carpenter, D. J., Senda, T., Sun, X., Ho, S.-H., Lerner, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.078 · Cited by 1,068
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
Self-citation
Cited by
Hu, Z., Chen, G., Zhao, Y., Gao, H., Li, L., Yin, Y., Jiang, J., Wang, L., Mang, Y., Gao, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01759-1 · Cited by 327
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“The ratio of these CD103 + T RM cells to poorly functional PD-1 high exhausted T cells was associated with a superior outcome among the ten patients receiving nivolumab in this study 121 .”
BackgroundLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis
Huang, B., Lyu, Z., Qian, Q., Chen, Y., Zhang, J., Li, B., Li, Y., Liang, J., Liu, Q., Li, Y., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.014 · Cited by 60
Kremer, K. N., Khammash, H. A., Miranda, A. M., Rutt, L. N., Twardy, S. M., Anton, P. E., Campbell, M. L., Garza-Ortiz, C., Orlicky, D. J., Pelanda, R., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1497788 · Cited by 19
Metadata
- Authors
- Barsch, M., Salié, H., Schlaak, A. E., Zhang, Z., Hess, M., Mayer, L. S., Tauber, C., Otto-Mora, P., Ohtani, T., Nilsson, T., Wischer, L., Winkler, F., Manne, S., Rech, A., Schmitt-Graeff, A., Bronsert, P., Hofmann, M., Neumann-Haefelin, C., Boettler, T., Fichtner-Feigl, S., van Boemmel, F., Berg, T., Rimassa, L., Di Tommaso, L., Saeed, A., D’Alessio, A., Pinato, D. J., Bettinger, D., Binder, H., John Wherry, E., Schultheiss, M., Thimme, R., & Bengsch, B.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 77
- Issue
- 2
- Pages
- 397-409
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4221039330
- Cited by
- 186
- References
- 14
- FWCI
- 15.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.